Selumetinib azd6244 s1008

Manufactured by Selleck Chemicals

Selumetinib (AZD6244 #S1008) is a potent and selective inhibitor of mitogen-activated protein kinase kinase (MEK). It is a white to off-white solid.

Automatically generated - may contain errors

Lab products found in correlation

Vemurafenib plx4032 s1267, by Selleck Chemicals (1 mentions) Trametinib gsk1120212 s2673, by Selleck Chemicals (1 mentions) Pd0325901 s1036, by Selleck Chemicals (1 mentions) Celltiter glo luminescent cell viability assay kit, by Promega (1 mentions)

Spelling variants of this product

AZD6244 (145 citations) Selumetinib (134 citations) Selumetinib (AZD6244) (30 citations) Selumetinib (S1008) (2 citations) S1008 (2 citations)

2 protocols using selumetinib azd6244 s1008

Inhibition of BRAF, MEK, and DUSP1 in Cancer

Check if the same lab product or an alternative is used in the 5 most similar protocols

BRAF inhibitor, Vemurafenib (PLX4032 #S1267) and MEK inhibitor, Selumetinib (AZD6244 #S1008) were from Selleckchem (Houston, TX). DUSP1 inhibitor BCI [(E)-2-benzylidene-3-(cyclohexylamino)-2,3-dihydro-1H-inden-1-one] (#NSC 150117) was obtained from Axon Medchem (Reston, VA).

Singh M.K., Altameemi S., Lares M., Newton M.A, & Setaluri V. (2022). Role of dual specificity phosphatases (DUSPs) in melanoma cellular plasticity and drug resistance. Scientific Reports, 12, 14395.

+ Open protocol

+ Expand

Evaluating MEK Inhibitor Cytotoxicity

Check if the same lab product or an alternative is used in the 5 most similar protocols

For drug treatment assays, cells were plated at a density of 2500 cells per well in a 96-well assay plate. The following day, cells were treated with the corresponding MEK1 inhibitors: selumetinib (AZD6244) S1008, trametinib (GSK1120212) S2673, and PD0325901 S1036 from Selleck Chemicals and refametinib (RDEA119) from Chemie Tek. Control wells were treated with dimethylsulfoxide (DMSO). Cell viability was assayed 6 days after drug treatment with CellTiter-Glo Luminescent Cell Viability Assay kit (Promega). Viability was normalized to DMSO controls. IC₅₀ estimates were obtained using least-squares nonlinear regression on a standard 4-parameter logistic model.

Gannon H.S., Kaplan N., Tsherniak A., Vazquez F., Weir B.A., Hahn W.C, & Meyerson M. (2015). Identification of an “Exceptional Responder” Cell Line to MEK1 Inhibition: Clinical Implications for MEK-targeted Therapy. Molecular cancer research : MCR, 14(2), 207-215.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!